Free Content Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study [Short communication]

Authors: Bachhuber, M.A.; Gross, R.

Source: The International Journal of Tuberculosis and Lung Disease, Volume 13, Number 8, August 2009 , pp. 1038-1040(3)

Publisher: International Union Against Tuberculosis and Lung Disease

Buy & download fulltext article:

Free content The full text is free.

View now:
PDF 239.6kb 

Abstract:

A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated meta-analyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

Keywords: isoniazid; HIV; tuberculosis; mortality

Document Type: Short communication

Affiliations: 1: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Publication date: 2009-08-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page